Sign in
Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy
Michael W. Stewart, MD
Annual Meeting Talks
2019
The Changing Avastin Landscape
Paul Hahn, MD, PhD, FASRS
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
2021
Category: AMD-Neovascular